{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:04:14Z","timestamp":1789621454758,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011946","name":"Abbott Diabetes Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13300-024-01677-5","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T09:49:11Z","timestamp":1734428951000},"page":"169-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective"],"prefix":"10.1007","volume":"16","author":[{"given":"Stewart","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sal","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Szafranski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-832X","authenticated-orcid":false,"given":"Yeesha","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"1677_CR1","unstructured":"Canadian Chronic Disease Surveillance System (CCDSS) Diabetes mellitus (types combined), excluding gestational diabetes, crude prevalence, percent, age 1 year and older, Canada. 2024. https:\/\/health-infobase.canada.ca\/ccdss\/data-tool\/. Accessed 24 Sep 2024."},{"key":"1677_CR2","unstructured":"Diabetes Canada. Diabetes: a present and growing threat to Canada\u2019s economy. 2018. https:\/\/www.ourcommons.ca\/Content\/Committee\/421\/FINA\/Brief\/BR10004340\/br-external\/DiabetesCanada-e.pdf. Accessed 24 Sep 2024."},{"key":"1677_CR3","unstructured":"Diabetes Canada. Reducing the risk of type 2 diabetes through workplace programs: a position statement. 2022. https:\/\/www.diabetes.ca\/DiabetesCanadaWebsite\/media\/Advocacy-and-Policy\/Diabetes-Canada-Workplace-Programs-Position-Statement-Jan-2022.pdf. Accessed 24 Sep 2024."},{"key":"1677_CR4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40200-015-0172-z","volume":"14","author":"JE Ward","year":"2015","unstructured":"Ward JE, Stetson BA, Mokshagundam SP. Patient perspectives on self-monitoring of blood glucose: perceived recommendations, behaviors and barriers in a clinic sample of adults with type 2 diabetes. J Diabetes Metab Disord. 2015;14:43.","journal-title":"J Diabetes Metab Disord"},{"issue":"Suppl 2","key":"1677_CR5","first-page":"S3","volume":"18","author":"D Rodbard","year":"2016","unstructured":"Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18(Suppl 2):S3\u201313.","journal-title":"Diabetes Technol Ther"},{"key":"1677_CR6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13300-019-00720-0","volume":"11","author":"M Evans","year":"2020","unstructured":"Evans M, Welsh Z, Ells S, Seibold A. The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11:83\u201395.","journal-title":"Diabetes Ther"},{"key":"1677_CR7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002590","volume":"10","author":"AL Carlson","year":"2022","unstructured":"Carlson AL, Daniel TD, DeSantis A, et al. Flash glucose monitoring in type 2 diabetes managed with basal insulin in the USA: a retrospective real-world chart review study and meta-analysis. BMJ Open Diabetes Res Care. 2022;10: e002590.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1677_CR8","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.2337\/dc20-0738","volume":"43","author":"H Deshmukh","year":"2020","unstructured":"Deshmukh H, Wilmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Diabetes Care. 2020;43:2153\u201360.","journal-title":"Diabetes Care"},{"key":"1677_CR9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","volume":"8","author":"T Haak","year":"2017","unstructured":"Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55\u201373.","journal-title":"Diabetes Ther"},{"key":"1677_CR10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-001115","volume":"8","author":"E Wada","year":"2020","unstructured":"Wada E, Onoue T, Kobayashi T, et al. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2020;8: e001115.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1677_CR11","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","volume":"388","author":"J Bolinder","year":"2016","unstructured":"Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr\u00f6ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254\u201363.","journal-title":"Lancet"},{"key":"1677_CR12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002580","volume":"10","author":"R Blissett","year":"2022","unstructured":"Blissett R, Blissett D, Levrat-Guillen F, et al. FreeStyle Libre Flash Glucose Monitoring system for people with type 1 diabetes in the UK: a budget impact analysis. BMJ Open Diabetes Res Care. 2022;10: e002580.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1677_CR13","doi-asserted-by":"crossref","unstructured":"Guerci B, Roussel R, Levrat-Guillen F, et al. Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technol Ther. 2023;25:20\u201330.","DOI":"10.1089\/dia.2022.0271"},{"key":"1677_CR14","doi-asserted-by":"crossref","first-page":"bvab013","DOI":"10.1210\/jendso\/bvab013","volume":"5","author":"RM Bergenstal","year":"2021","unstructured":"Bergenstal RM, Kerr MSD, Roberts GJ, Souto D, Nabutovsky Y, Hirsch IB. Flash CGM Is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc. 2021;5:bvab013.","journal-title":"J Endocr Soc."},{"key":"1677_CR15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajmo.2022.100008","volume":"9","author":"E Miller","year":"2023","unstructured":"Miller E, Roberts GJ, Joseph JM, et al. Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes. Am J Med Open. 2023;9: 100008.","journal-title":"Am J Med Open"},{"key":"1677_CR16","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.2337\/dc21-2341","volume":"45","author":"MA Rotondi","year":"2022","unstructured":"Rotondi MA, Wong O, Riddell M, Perkins B. Population-level impact and cost-effectiveness of continuous glucose monitoring and intermittently scanned continuous glucose monitoring technologies for adults with type 1 diabetes in canada: a modeling study. Diabetes Care. 2022;45:2012\u20139.","journal-title":"Diabetes Care"},{"key":"1677_CR17","unstructured":"Canadian Institute for Health Information. National expenditure trends 1975\u20132019. 2019. https:\/\/www.cihi.ca\/sites\/default\/files\/document\/nhex-trends-narrative-report-2019-en.pdf. Accessed 11 Nov 2024."},{"key":"1677_CR18","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jval.2024.01.010","volume":"27","author":"K Szafranski","year":"2024","unstructured":"Szafranski K, De Pouvourville G, Greenberg D, et al. The determination of diabetes utilities, costs, and effects model: a cost-utility tool using patient-level microsimulation to evaluate sensor-based glucose monitoring systems in type 1 and type 2 diabetes: comparative validation. Value Health. 2024;27:500\u20137.","journal-title":"Value Health"},{"key":"1677_CR19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/dme.12371","volume":"31","author":"P Thokala","year":"2014","unstructured":"Thokala P, Kruger J, Brennan A, et al. Assessing the cost-effectiveness of type 1 diabetes interventions: the Sheffield type 1 diabetes policy model. Diabet Med. 2014;31:477\u201386.","journal-title":"Diabet Med"},{"key":"1677_CR20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/diacare.22.1.99","volume":"22","author":"EDIC Research Group","year":"1999","unstructured":"EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99\u2013111.","journal-title":"Diabetes Care"},{"key":"1677_CR21","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.ophtha.2008.08.023","volume":"115","author":"R Klein","year":"2008","unstructured":"Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008;115:1859\u201368.","journal-title":"Ophthalmology"},{"key":"1677_CR22","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S2213-8587(17)30221-8","volume":"5","author":"S Basu","year":"2017","unstructured":"Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017;5:788\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1677_CR23","unstructured":"Tikkane R, Osborn R, Mossialos E, Djordjevic A, Wharton G. International health care system profiles: Canada. 2020. https:\/\/www.commonwealthfund.org\/international-health-policy-center\/countries\/canada. Accessed 11 Nov 2024."},{"key":"1677_CR24","unstructured":"CDA. Procedures for reimbursement reviews. 2024. https:\/\/cadth.ca\/sites\/default\/files\/Drug_Review_Process\/CADTH_Drug_Reimbursement_Review_Procedures.pdf. Accessed 24 Sep 2024."},{"key":"1677_CR25","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/ndt\/gfp709","volume":"25","author":"AJ Ahola","year":"2010","unstructured":"Ahola AJ, Saraheimo M, Forsblom C, Hietala K, Sintonen H, Groop PH. Health-related quality of life in patients with type 1 diabetes\u2013association with diabetic complications (the FinnDiane Study). Nephrol Dial Transplant. 2010;25:1903\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"1677_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clinthera.2018.12.014","volume":"41","author":"D Brixner","year":"2019","unstructured":"Brixner D, Ermakova A, Xiong Y, et al. Clinical and economic outcomes of patients with type 2 diabetes on multiple daily injections of basal-bolus insulin (MDI) therapy: a retrospective cohort study. Clin Ther. 2019;41:303-13.e1.","journal-title":"Clin Ther"},{"key":"1677_CR27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.14949","volume":"25","author":"R Aronson","year":"2023","unstructured":"Aronson R, Brown RE, Chu L, et al. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): a randomized controlled trial. Diabetes Obes Metab. 2023;25:1024\u201331.","journal-title":"Diabetes Obes Metab"},{"key":"1677_CR28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s13300-022-01253-9","volume":"13","author":"M Evans","year":"2022","unstructured":"Evans M, Welsh Z, Seibold A. Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies. Diabetes Ther. 2022;13:1175\u201385.","journal-title":"Diabetes Ther"},{"key":"1677_CR29","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2337\/dc20-1690","volume":"44","author":"R Roussel","year":"2021","unstructured":"Roussel R, Riveline JP, Vicaut E, et al. Important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care. 2021;44:1368\u201376.","journal-title":"Diabetes Care"},{"key":"1677_CR30","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.2337\/dc16-2793","volume":"40","author":"ML Jensen","year":"2017","unstructured":"Jensen ML, Persson F, Andersen GS, et al. Incidence of ketoacidosis in the danish type 2 diabetes population before and after introduction of sodium-glucose cotransporter 2 inhibitors\u2014a nationwide, retrospective cohort study, 1995\u20132014. Diabetes Care. 2017;40:e57\u20138.","journal-title":"Diabetes Care"},{"key":"1677_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126427","volume":"10","author":"CL Edridge","year":"2015","unstructured":"Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS ONE. 2015;10: e0126427.","journal-title":"PLoS ONE"},{"key":"1677_CR32","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2337\/dc19-0830","volume":"42","author":"JH Pettus","year":"2019","unstructured":"Pettus JH, Zhou FL, Shepherd L, et al. Incidences of severe hypoglycemia and diabetic ketoacidosis and prevalence of microvascular complications stratified by age and glycemic control in U.S. adult patients with type 1 diabetes: a real-world study. Diabetes Care. 2019;42:2220\u20137.","journal-title":"Diabetes Care"},{"key":"1677_CR33","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/imj.14842","volume":"51","author":"I Sagy","year":"2021","unstructured":"Sagy I, Zimhony-Nissim N, Brandstaetter E, et al. Outcomes of diabetic ketoacidosis in a tertiary centre with restricted intensive care unit bed capacity. Intern Med J. 2021;51:948\u201354.","journal-title":"Intern Med J"},{"key":"1677_CR34","doi-asserted-by":"crossref","unstructured":"Wright AD, Cull CA, Macleod KM, Holman RR. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2006;20:395\u2013401.","DOI":"10.1016\/j.jdiacomp.2005.08.010"},{"key":"1677_CR35","doi-asserted-by":"crossref","unstructured":"Bilir SP, Hellmund R, Wehler B, Li H, Munakata J, Lamotte M. Cost-effectiveness analysis of a flash glucose monitoring system for patients with type 1 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14:73\u20139.","DOI":"10.17925\/EE.2018.14.2.73"},{"key":"1677_CR36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000809","volume":"7","author":"M Fokkert","year":"2019","unstructured":"Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care. 2019;7: e000809.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1677_CR37","first-page":"589","volume":"16","author":"TB Gibson","year":"2010","unstructured":"Gibson TB, Song X, Alemayehu B, et al. Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care. 2010;16:589\u2013600.","journal-title":"Am J Manag Care"},{"key":"1677_CR38","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.24025:1-12","author":"J Frank","year":"2024","unstructured":"Frank J, Son D, Szafranski K, Poon Y. Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: a microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid. J Manag Care Spec Pharm. 2024. https:\/\/doi.org\/10.18553\/jmcp.2024.24025:1-12.","journal-title":"J Manag Care Spec Pharm"},{"key":"1677_CR39","doi-asserted-by":"publisher","unstructured":"Del Prato S, Giorgino F, Szafranski K, Poon Y. Cost-utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy\u2014an Italian healthcare system perspective. Diabetes Obes Metab. 2024. https:\/\/doi.org\/10.1111\/dom.15703.","DOI":"10.1111\/dom.15703"},{"key":"1677_CR40","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1080\/09687599.2012.741518","volume":"28","author":"C Benoit","year":"2012","unstructured":"Benoit C, Jansson M, Jansenberger M, Phillips R. Disability stigmatization as a barrier to employment equity for legally-blind Canadians. Disabil Soc. 2012;28:970\u201383.","journal-title":"Disabil Soc"},{"key":"1677_CR41","doi-asserted-by":"crossref","first-page":"205031211774497","DOI":"10.1177\/2050312117744978","volume":"5","author":"R Reibis","year":"2017","unstructured":"Reibis R, Kuhl U, Salzwedel A, et al. Return to work in heart failure patients with suspected viral myocarditis. SAGE Open Med. 2017;5:2050312117744978.","journal-title":"SAGE Open Med"},{"key":"1677_CR42","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1161\/CIRCOUTCOMES.115.002611","volume":"9","author":"RP Dreyer","year":"2016","unstructured":"Dreyer RP, Xu X, Zhang W, et al. Return to work after acute myocardial infarction: comparison between young women and men. Circ Cardiovasc Qual Outcomes. 2016;9:S45-52.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1677_CR43","doi-asserted-by":"crossref","first-page":"205435811770398","DOI":"10.1177\/2054358117703986","volume":"4","author":"B Manns","year":"2017","unstructured":"Manns B, McKenzie SQ, Au F, et al. The financial impact of advanced kidney disease on canada pension plan and private disability insurance costs. Can J Kidney Health Dis. 2017;4:2054358117703986.","journal-title":"Can J Kidney Health Dis"},{"key":"1677_CR44","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/09638280701320797","volume":"29","author":"H Burger","year":"2007","unstructured":"Burger H, Marincek C. Return to work after lower limb amputation. Disabil Rehabil. 2007;29:1323\u20139.","journal-title":"Disabil Rehabil"},{"key":"1677_CR45","doi-asserted-by":"crossref","unstructured":"Duong P, Sauv\u00e9-Schenk K, Egan MY, Meyer MJ, Morrison T. Operational definitions and estimates of return to work poststroke: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2019;100:1140\u201352.","DOI":"10.1016\/j.apmr.2018.09.121"},{"key":"1677_CR46","unstructured":"Deloitte. The cost of vision loss and blindness in Canada: Canadian Council of the Blind. 2021. https:\/\/www.fightingblindness.ca\/wp-content\/uploads\/2021\/12\/Deloitte-Cost-of-vision-loss-and-blindness-in-Canada-report-May-2021.pdf. Accessed 24 Sep 2024."},{"key":"1677_CR47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12913-015-0687-5","volume":"15","author":"RB Hopkins","year":"2015","unstructured":"Hopkins RB, Burke N, Harlock J, Jegathisawaran J, Goeree R. Economic burden of illness associated with diabetic foot ulcers in Canada. BMC Health Serv Res. 2015;15:13.","journal-title":"BMC Health Serv Res"},{"key":"1677_CR48","doi-asserted-by":"crossref","first-page":"E826","DOI":"10.9778\/cmajo.20200230","volume":"9","author":"AR Levy","year":"2021","unstructured":"Levy AR, Johnston KM, Daoust A, et al. Health expenditures after first hospital admission for heart failure in Nova Scotia, Canada: a retrospective cohort study. CMAJ Open. 2021;9:E826\u201333.","journal-title":"CMAJ Open"},{"key":"1677_CR49","doi-asserted-by":"crossref","first-page":"205435811983552","DOI":"10.1177\/2054358119835521","volume":"6","author":"B Manns","year":"2019","unstructured":"Manns B, Hemmelgarn B, Tonelli M, et al. The cost of care for people with chronic kidney disease. Can J Kidney Health Dis. 2019;6:2054358119835521.","journal-title":"Can J Kidney Health Dis"},{"key":"1677_CR50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s41669-017-0061-0","volume":"2","author":"DT Tran","year":"2018","unstructured":"Tran DT, Ohinmaa A, Thanh NX, Welsh RC, Kaul P. The healthcare cost burden of acute myocardial infarction in Alberta. Canada Pharmacoecon Open. 2018;2:433\u201342.","journal-title":"Canada Pharmacoecon Open"},{"key":"1677_CR51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12913-021-06669-w","volume":"21","author":"AYX Yu","year":"2021","unstructured":"Yu AYX, Krahn M, Austin PC, et al. Sex differences in direct healthcare costs following stroke: a population-based cohort study. BMC Health Serv Res. 2021;21:619.","journal-title":"BMC Health Serv Res"},{"key":"1677_CR52","unstructured":"Statistics Canada. Average earnings, 1998 to 2021. 2022. https:\/\/www150.statcan.gc.ca\/n1\/pub\/14-28-0001\/2020001\/article\/00006-eng.htm. Accessed 24 Sep 2024."},{"key":"1677_CR53","unstructured":"Ministry of Health. Ontario Health Insurance Plan. Ontario drug programs reference manual\u2014revision #9. Toronto: Ministry of Health; 2023."},{"key":"1677_CR54","unstructured":"Diabetes Canada. Coverage of self-monitoring of blood glucose (SMBG) strips. 2020. https:\/\/www.diabetes.ca\/DiabetesCanadaWebsite\/media\/Advocacy-and-Policy\/Advocacy%20Reports\/Pro-Comparison-Test-Strips-Comparison-EN.pdf. Accessed 24 Sep 2024."},{"key":"1677_CR55","unstructured":"Diabetes Depot. Test strips, lancets & FREE meters. 2021. www.diabetesdepot.org. Accessed 24 Sep 2024."},{"key":"1677_CR56","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0272989X16658660","volume":"36","author":"T Peasgood","year":"2016","unstructured":"Peasgood T, Brennan A, Mansell P, Elliott J, Basarir H, Kruger J. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Making. 2016;36:1020\u201333.","journal-title":"Med Decis Making"},{"key":"1677_CR57","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.clinthera.2014.07.019","volume":"36","author":"ST Brown","year":"2014","unstructured":"Brown ST, Grima DG, Sauriol L. Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus. Clin Ther. 2014;36:1576\u201387.","journal-title":"Clin Ther"},{"key":"1677_CR58","unstructured":"CDA. New drugs for type 2 diabetes: second-line therapy\u2014science report. 2017. https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/TR0012_T2D_Science_Report.pdf. Accessed 24 Sep 2024."},{"key":"1677_CR59","doi-asserted-by":"crossref","unstructured":"Jorissen W, Annemans L, Louis N, Nilsson A, Willis M. Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with canagliflozin in Belgium. Acta Clin Belg. 2022;77:945\u201354.","DOI":"10.1080\/17843286.2021.2015554"},{"key":"1677_CR60","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016766","volume":"8","author":"DJ Pollard","year":"2018","unstructured":"Pollard DJ, Brennan A, Dixon S, et al. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial. BMJ Open. 2018;8: e016766.","journal-title":"BMJ Open"},{"key":"1677_CR61","doi-asserted-by":"crossref","unstructured":"Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating quality of life decrements due to diabetes complications in the United States: The health utility index (HUI) diabetes complication equation. Pharmacoeconomics. 2019;37:921\u20139.","DOI":"10.1007\/s40273-019-00775-8"},{"key":"1677_CR62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jval.2016.10.007","volume":"20","author":"LS Matza","year":"2017","unstructured":"Matza LS, Stewart KD, Davies EW, Hellmund R, Polonsky WH, Kerr D. Health state utilities associated with glucose monitoring devices. Value Health. 2017;20:507\u201311.","journal-title":"Value Health"},{"key":"1677_CR63","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1185\/030079906X115757","volume":"22","author":"CJ Currie","year":"2006","unstructured":"Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22:1523\u201334.","journal-title":"Curr Med Res Opin"},{"key":"1677_CR64","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/027298902400448902","volume":"22","author":"P Clarke","year":"2002","unstructured":"Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340\u20139.","journal-title":"Med Decis Making"},{"key":"1677_CR65","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","volume":"9","author":"B Van der Schueren","year":"2021","unstructured":"Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021;9:776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1677_CR66","doi-asserted-by":"crossref","unstructured":"Au NH, Ratzki-Leewing A, Zou G, et al. Real-world incidence and risk factors for daytime and nocturnal non-severe hypoglycemia in adults with type 2 diabetes mellitus on insulin and\/or secretagogues (InHypo-DM study, Canada). Can J Diabetes. 2022;46:196-203.e2.","DOI":"10.1016\/j.jcjd.2021.09.004"},{"key":"1677_CR67","doi-asserted-by":"crossref","unstructured":"Palmer AJ. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood Challenge Meeting. Value Health. 2013;16:670\u201385.","DOI":"10.1016\/j.jval.2013.01.002"},{"key":"1677_CR68","doi-asserted-by":"crossref","unstructured":"Si L, Willis MS, Asseburg C, et al. Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the Ninth Mount Hood Diabetes Challenge. Value Health. 2020;23:1163\u201370.","DOI":"10.1016\/j.jval.2020.04.1832"},{"key":"1677_CR69","doi-asserted-by":"crossref","unstructured":"Alshannaq H, Isitt JJ, Pollock RF, et al. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated type 2 diabetes in Canada. J Comp Eff Res. 2023;12: e230075.","DOI":"10.57264\/cer-2023-0075"},{"key":"1677_CR70","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2147\/CEOR.S304395","volume":"13","author":"S Roze","year":"2021","unstructured":"Roze S, Isitt JJ, Smith-Palmer J, Lynch P. Evaluation of the long-term cost-effectiveness of the Dexcom g6 continuous glucose monitor versus self-monitoring of blood glucose in people with type 1 diabetes in Canada. Clinicoecon Outcomes Res. 2021;13:717\u201325.","journal-title":"Clinicoecon Outcomes Res"},{"key":"1677_CR71","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/dia.2018.0328","volume":"21","author":"J Jendle","year":"2019","unstructured":"Jendle J, P\u00f6hlmann J, de Portu S, Smith-Palmer J, Roze S. Cost-effectiveness analysis of the Minimed 670g hybrid closed-loop system versus continuous subcutaneous insulin infusion for treatment of type 1 diabetes. Diabetes Technol Ther. 2019;21:110\u20138.","journal-title":"Diabetes Technol Ther"},{"key":"1677_CR72","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/13696998.2021.1939706","volume":"24","author":"S Roze","year":"2021","unstructured":"Roze S, Buompensiere MI, Ozdemir Z, de Portu S, Cohen O. Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK. J Med Econ. 2021;24:883\u201390.","journal-title":"J Med Econ"},{"key":"1677_CR73","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15232","volume":"41","author":"RA Elliott","year":"2024","unstructured":"Elliott RA, Rogers G, Evans ML, et al. Estimating the cost-effectiveness of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in England. Diabet Med. 2024;41: e15232.","journal-title":"Diabet Med"},{"key":"1677_CR74","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s13300-022-01325-w","volume":"13","author":"R Ajjan","year":"2022","unstructured":"Ajjan R, Bilir SP, Hellmund R, Souto D. Cost-effectiveness analysis of flash glucose monitoring system for people with type 2 diabetes receiving intensive insulin treatment. Diabetes Ther. 2022;13:1933\u201345.","journal-title":"Diabetes Ther"},{"key":"1677_CR75","first-page":"80","volume":"14","author":"SP Bilir","year":"2018","unstructured":"Bilir SP, Hellmund R, Wehler E, Li H, Munakata J, Lamotte M. The cost-effectiveness of a flash glucose monitoring system for management of patients with type 2 diabetes receiving intensive insulin treatment in Sweden. Eur Endocrinol. 2018;14:80\u20135.","journal-title":"Eur Endocrinol"},{"key":"1677_CR76","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1089\/dia.2021.0263","volume":"23","author":"JR Frank","year":"2021","unstructured":"Frank JR, Blissett D, Hellmund R, Virdi N. Budget impact of the flash continuous glucose monitoring system in medicaid diabetes beneficiaries treated with intensive insulin therapy. Diabetes Technol Ther. 2021;23:S36\u201344.","journal-title":"Diabetes Technol Ther"},{"key":"1677_CR77","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1111\/dom.15268","volume":"25","author":"A Ratzki-Leewing","year":"2023","unstructured":"Ratzki-Leewing A, Black JE, Kahkoska AR, et al. Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States). Diabetes Obes Metab. 2023;25:3736\u201347.","journal-title":"Diabetes Obes Metab"},{"key":"1677_CR78","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jcjd.2021.07.003","volume":"45","author":"AYY Cheng","year":"2021","unstructured":"Cheng AYY, Feig DS, Ho J, Siemens R, Diabetes Canada Clinical Practice Guidelines Expert Working Group. Diabetes Canada Clinical Practice Guidelines Steering Committee. Blood glucose monitoring in adults and children with diabetes: update 2021. Can J Diabetes. 2021;45:580\u20137.","journal-title":"Can J Diabetes"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01677-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T09:20:45Z","timestamp":1738660845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01677-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1677"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01677-5","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stewart Harris reports consulting with Abbott, Bayer, Dexcom, Eli Lilly, Novo Nordisk, and Sanofi and research grants from BIO, Eli Lilly, Novo Nordisk, and Novartis. Sal Cimino is a clinical pharmacist and a senior consultant at MORSE Consulting, which has received an honorarium from Abbott to participate in an advisory board for this study. Yen Nguyen is a clinical pharmacist and the president of Synergyx Consulting, which has received an honorarium from Abbott to participate in an advisory board for this study. Yeesha Poon is an employee and shareholder of Abbott. Kirk Szafranski is an employee of Eversana, which has received project funding from Abbott.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The clinical trials from which data were taken for this analysis were conducted in accordance with the Declaration of Helsinki, with the relevant consents obtained from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}